Taligen Announces Key Additions to Management Team

- Expands Product Development Expertise -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has strengthened its management team with the addition of Sven Ante (Bill) Lundberg, MD as Chief Medical Officer and Karen Tubridy, PharmD, as Vice President, Clinical Operations and Regulatory Affairs.

“We are pleased to have attracted such experienced clinical development experts as Dr’s Lundberg and Tubridy to Taligen,” said Abbie Celniker, Ph.D., President and CEO of Taligen. “They bring a combined 35 years of biopharmaceutical product development experience that includes the development of over 20 novel drugs with strong expertise in clinical strategy, clinical operations, regulatory and commercial medical affairs. Theirs skills and years of experience will be critical to our success as we move several of our clinical candidates into clinical development.”

Dr. Lundberg has held senior clinical and medical affairs roles in both large pharmaceutical and emerging biopharmaceutical companies, including Genzyme, Wyeth, Xanthus Pharmaceuticals and most recently, Antisoma Research Ltd after the acquisition of Xanthus in 2008. Dr. Lundberg brings a wealth of knowledge and experience in the fields of immunology and oncology. He received clinical training in internal medicine and oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, both at Harvard Medical School, and has held Research and Clinical Fellowship positions in Immunology and Oncology at the Dana-Farber Cancer Institute (Harvard Medical School) and the Whitehead Institute (MIT). Dr. Lundberg holds a B.S. degree in biology from the Massachusetts Institute of Technology and an MD from Stanford Medical School.

Dr. Tubridy has held clinical operations leadership and management roles within the biopharmaceutical industry for over twenty years with a particular emphasis in the areas of hematology, immunology and oncology. Prior to joining Taligen, Dr. Tubridy served as Senior Director of Clinical Operations for Biogen Idec’s Hemophilia franchise and Vice President of Clinical Operations at Syntonix Pharmaceuticals. Prior to Syntonix, Dr. Tubridy held management positions in global medical affairs and clinical development at AVANT Immunotherapeutics and Wyeth/Genetics Institute. Dr. Tubridy received her B.S. and PharmD degrees in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, Boston, MA.

About Taligen Therapeutics

Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen’s targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. For additional information about the Company, please visit www.taligentherapeutics.com.



CONTACT:

The Yates Network
Gina Nugent, 617-460-3579

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Suggested Articles

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.